Search Orphan Drug Designations and Approvals
-
Generic Name: | human monoclonal antibody targeting human sclerostin |
---|---|
Date Designated: | 02/29/2016 |
Orphan Designation: | Treatment of osteogenesis imperfecta. |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Ultragenyx Pharmaceutical, Inc. 60 Leveroni Ct Novato, California 94949 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-